Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Testar kombinationen av Belinostat och SGI-110 (Guadecitabine) eller ASTX727 för behandling av inoperabelt och metastaserande konventionellt kondrosarkom

17 november 2026 uppdaterad av: National Cancer Institute (NCI)

En fas 2-studie av Belinostat och SGI-110 (Guadecitabine) eller ASTX727 för behandling av inoperabelt och metastaserande konventionellt kondrosarkom

This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread from where it first started (primary site) to other places in the body (metastatic). Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as guadecitabine and ASTX727, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving belinostat in combination with guadecitabine or ASTX727 may lower the chance of unresectable and metastatic chondrosarcoma growing or spreading.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To conduct a phase 2 clinical trial to evaluate whether combination treatment with belinostat and decitabine and cedazuridine (ASTX727) shows preliminary evidence of clinical activity in unresectable or metastatic conventional chondrosarcoma (CS) using an objective response rate endpoint.

SECONDARY OBJECTIVES:

I. To evaluate the toxicity profile associated with the belinostat and ASTX727. II. To evaluate the progression free survival (PFS) associated with the belinostat and ASTX727.

III. To evaluate the toxicity profile, objective response rate and progression free survival among the initial six patients treated with belinostat and SGI-110 (guadecitabine) prior to Amendment 5 in which ASTX727 was substituted for SGI-110 (guadecitabine).

CORRELATIVE OBJECTIVES:

I. To determine the IDH1/2 mutational status of subject's tumors and to evaluate for a relationship between presence of IDH1/2 mutation and clinical benefit from study treatment.

II. To conduct ribonucleic acid sequencing (RNAseq) analysis using baseline and on-treatment tissue biopsies to study the effects of study treatment on CS gene expression patterns and identify candidate genes which may underlie treatment efficacy.

III. To evaluate for changes in global deoxyribonucleic acid (DNA) methylation levels using baseline and on-treatment biopsies and correlate changes in global methylation with clinical benefit from study treatment.

IV. To use multiplex immunohistochemistry to interrogate the immune microenvironment in baseline and on-treatment tissue biopsies to define changes in infiltrating immune cell subsets and PD-L1/major histocompatibility complex (MHC) expression by immune and tumor cells associated with study treatment.

OUTLINE:

Patients receive guadecitabine subcutaneously (SC) or ASTX727 orally (PO) on days 1-5. Patients also receive belinostat intravenously (IV) over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and magnetic resonance imaging (MRI) or computed tomography (CT) throughout the trial.

After completion of study treatment, patients are followed up every 3 months for 24 months.

Studietyp

Interventionell

Inskrivning (Faktisk)

19

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85054
        • Mayo Clinic Hospital in Arizona
    • California
      • Duarte, California, Förenta staterna, 91010
        • City of Hope Comprehensive Cancer Center
      • Los Angeles, California, Förenta staterna, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Förenta staterna, 90033
        • Los Angeles General Medical Center
      • Newport Beach, California, Förenta staterna, 92663
        • USC Norris Oncology/Hematology-Newport Beach
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • UCHealth University of Colorado Hospital
    • Connecticut
      • New Haven, Connecticut, Förenta staterna, 06520
        • Yale University
    • Florida
      • Coral Gables, Florida, Förenta staterna, 33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach, Florida, Förenta staterna, 33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Jacksonville, Florida, Förenta staterna, 32224-9980
        • Mayo Clinic in Florida
      • Miami, Florida, Förenta staterna, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Plantation, Florida, Förenta staterna, 33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
      • Tampa, Florida, Förenta staterna, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern University
    • Kansas
      • Hays, Kansas, Förenta staterna, 67601
        • HaysMed
      • Kansas City, Kansas, Förenta staterna, 66160
        • University of Kansas Cancer Center
      • Lawrence, Kansas, Förenta staterna, 66044
        • Lawrence Memorial Hospital
      • Overland Park, Kansas, Förenta staterna, 66210
        • University of Kansas Cancer Center-Overland Park
      • Pittsburg, Kansas, Förenta staterna, 66762
        • Mercy Hospital Pittsburg
      • Salina, Kansas, Förenta staterna, 67401
        • Salina Regional Health Center
      • Topeka, Kansas, Förenta staterna, 66606
        • University of Kansas Health System Saint Francis Campus
      • Westwood, Kansas, Förenta staterna, 66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55905
        • Mayo Clinic in Rochester
    • Missouri
      • Creve Coeur, Missouri, Förenta staterna, 63141
        • Siteman Cancer Center at West County Hospital
      • Kansas City, Missouri, Förenta staterna, 64154
        • University of Kansas Cancer Center - North
      • Kansas City, Missouri, Förenta staterna, 64108
        • University Health Truman Medical Center
      • Lee's Summit, Missouri, Förenta staterna, 64064
        • University of Kansas Cancer Center - Lee's Summit
      • North Kansas City, Missouri, Förenta staterna, 64116
        • University of Kansas Cancer Center at North Kansas City Hospital
      • St Louis, Missouri, Förenta staterna, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Förenta staterna, 63129
        • Siteman Cancer Center-South County
    • New York
      • New York, New York, Förenta staterna, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Förenta staterna, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
    • Ohio
      • Columbus, Ohio, Förenta staterna, 43210
        • Ohio State University Comprehensive Cancer Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • University of Oklahoma Health Sciences Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
        • UPMC Hillman Cancer Center
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • UT MD Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84112
        • Huntsman Cancer Institute/University of Utah
    • Virginia
      • Richmond, Virginia, Förenta staterna, 23298
        • VCU Massey Comprehensive Cancer Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients must have biopsy-proven conventional chondrosarcoma (CS) which is:

    • Either metastatic or locally advanced and unresectable, and

    • Measurable at study entry according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, and

    • Amenable to biopsy with imaging guidance at no or acceptable risk to the patient as defined by institutional guidelines for research-related biopsies or the treating investigator's assessment

    • In addition, the following criteria must be met:

      • Patients must have at least one lesion measurable by RECIST version 1.1 criteria which has not been previously irradiated
      • Patients who have histologic evidence of grade 1 chondrosarcoma only must either be symptomatic from their disease in the opinion of the treating investigator or demonstrate radiographic evidence of disease progression in the 3 months prior to initiation of study treatment
    • Note: Pathology review and confirmation of diagnosis will occur at the site enrolling the patient on this study

  • Patients may have been treated with any number of prior systemic therapies. Because there are no Food and Drug Administration (FDA)-approved treatments for this disease, patients who have received no prior systemic therapy are also eligible. However, disease must be deemed surgically unresectable

  • Age >= 18 years. Chondrosarcoma is rarely encountered in children and adolescents

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,000/mm^3

  • Hemoglobin 8 g/dL

  • Platelet count >= 75,000/mm^3

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN

  • Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 45 mL/min/1.73 m^2

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, if patients have been clinically asymptomatic, and if patients have not received systemic corticosteroids for at least 28 days. Patients with brain metastases not meeting these criteria are not eligible

  • Patients must be disease-free of prior invasive malignancies for > 5 years, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

    • NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • The effects of belinostat and SGI-110 (guadecitabine) or ASTX727 on the developing human fetus are unknown. For this reason, and because the DNA methyltransferase inhibitor decitabine, the active metabolite of SGI-110 (guadecitabine) and a component of ASTX727, is known to be teratogenic, and because belinostat may cause teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing cells, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for at least 6 months after the last dose of study drugs. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of belinostat and SGI-110 (guadecitabine) or ASTX727 administration

  • Patients must be able to understand and willing to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients with dedifferentiated, mesenchymal, or clear cell chondrosarcoma are not eligible

  • Patients who have not recovered from adverse events (AEs) (i.e., have residual toxicities > grade 1) due to prior anti-cancer therapy are not allowed, with the exceptions of alopecia and endocrinopathies from prior immunotherapy-based treatments that are well-controlled with hormone replacement. In addition, the following time periods must elapse between the last dose of prior anti-cancer treatment and initiation of study treatment on this protocol:

    • Cytotoxic chemotherapy or biologic, including immunotherapy: 28 days
    • Small molecule targeted drug: 21 days or 5 half-lives, whichever is shorter. If 5 half-lives is shorter than 21 days, then 21 days applies.
    • Radiation: 28 days, except for palliative radiation, for which 14 days applies
  • Patients who are receiving any other investigational agents

  • Patients with known history of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to SGI-110 (guadecitabine), its active metabolite decitabine, or ASTX727, or belinostat

  • Chronic use of any medications or substances that are strong inhibitors of UGT1A1 is not allowed. Patients must switch to alternative medications 7-14 days before treatment with belinostat. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

  • Patients with any known UGT1A1 polymorphism, heterozygous or homozygous, associated with reduced function (UGT1A1*6, UGT1A1*28, or UGT1A1*60)

  • Patients with uncontrolled intercurrent illness

  • Patients with psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant women are excluded from this study because SGI-110 (guadecitabine) is a derivative of decitabine, and ASTX727 contains the agent decitabine, which has the potential for teratogenic or abortifacient effects, and because belinostat may cause teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing cells. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with SGI-110 (guadecitabine), ASTX727 and belinostat, breastfeeding should be discontinued

  • Prolongation of the heart-rate corrected QT (QTc) interval >= 450 ms (i.e., grade 1 or higher) on the screening electrocardiogram (ECG) prior to initiation of study treatment. If baseline QTc on screening ECG is >= 450 ms (i.e., grade 1 or higher):

    • Check potassium and magnesium serum levels, and
    • Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm a QTc interval < 450 ms

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment (belinostat, guadecitabine, ASTX727)

Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and MRI or CT throughout the trial.

Undergo CT

Andra namn:
  • CT
  • KATT
  • Datortomografi
  • Beräknad axiell tomografi
  • Datoriserad axialtomografi
  • tomografi
  • Datoriserad axiell tomografi (förfarande)
  • Datortomografi (CT) skanning
  • Diagnostisk kattskanning
  • Diagnostisk kattskanningstjänsttyp

Undergo MRI

Andra namn:
  • MRI
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medicinsk bildbehandling, magnetisk resonans / kärnmagnetisk resonans
  • HERR
  • MR-avbildning
  • MRI-skanning
  • NMR-avbildning
  • NMRI
  • Kärnmagnetisk resonanstomografi
  • Magnetisk resonanstomografi (MRT)
  • sMRI
  • Magnetisk resonanstomografi (förfarande)
  • Strukturell MRI

Undergo biopsy

Andra namn:
  • Bx
  • BIOPSY_TYPE
  • Biopsi

Undergo collection of blood

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling

Given PO

Andra namn:
  • ASTX727
  • CDA-hämmare E7727/Decitabin kombinationsmedel ASTX727
  • Cedazuridin/Decitabin kombinationsmedel ASTX727
  • Cedazuridin/Decitabin tablett
  • Inqovi
  • C-DEC
  • DEC-C
  • ASTX 727
  • ASTX-727
  • Inaqovi

Given IV

Andra namn:
  • PXD101
  • Beleodaq
  • PXD 101
  • PXD-101

Given SC

Andra namn:
  • SGI-110
  • DNMT-hämmare SGI-110
  • S110
  • SGI 110
  • SGI110

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate (ORR) in Belinostat, ASTX727
Tidsram: Within 6 months after initiating study treatment

Best Objective Response per RECIST Version 1.1 criteria. CR, complete response defined by the disappearance of all target lesions; PR, partial response defined by at least a 30% decrease in the sum of the diameters of target lesions; SD, stable disease defined by neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; PD, progressive disease defined by at least a 20% increase in the sum of the diameters of target lesions or the appearance of one or more new lesions.

Within 6 months after initiating study treatment

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Presence of Treatment Related Adverse Events (AEs) in Belinostat, ASTX727
Tidsram: Up to 24 months post treatment

Adverse events (AEs) in belinostat, ASTX727 were recorded at each clinical visit and were categorized according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The attribution of AEs to each of the study drugs was recorded and categorized as possibly, probably, or definitely related to treatment. AEs are reported as counts and percentages per AE by grade and the number of patients with a given maximal grade of toxicity.

Up to 24 months post treatment
Progression Free Survival (PFS) in Belinostat, ASTX727
Tidsram: Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.

PFS is defined as the time from first treatment with the study drug to the earliest of either disease progression or death from any cause. Patients who are alive and progression free will be censored at the time of their last follow-up. The Kaplan-Meier method was used to evaluate time to event endpoints. Median PFS was reported with a 95% confidence interval. Data will be presented as Kaplan Meier plots.

Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.
Presence of Treatment Related Adverse Events (AEs) in Belinostat, SGI-110
Tidsram: Up to 24 months post treatment

Adverse events (AEs) from belinostat, SGI-110 were recorded at each clinical visit and were categorized according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The attribution of AEs to each of the study drugs was recorded and categorized as possibly, probably, or definitely related to treatment. AEs are reported as counts and percentages per AE by grade and the number of patients with a given maximal grade of toxicity.

Up to 24 months post treatment
Progression Free Survival (PFS) in Belinostat, SGI-110
Tidsram: Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.

PFS is defined as the time from first treatment with the study drug to the earliest of either disease progression or death from any cause. Patients who are alive and progression free will be censored at the time of their last follow-up. The Kaplan-Meier method was used to evaluate time to event endpoints. Median PFS was reported with a 95% confidence interval. Data will be presented as Kaplan Meier plots.

Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.
Objective Response Rate (ORR) in Belinostat, SGI-110
Tidsram: Within 6 months after initiating study treatment.

Best Objective Response per RECIST Version 1.1 criteria. CR, complete response defined by the disappearance of all target lesions; PR, partial response defined by at least a 30% decrease in the sum of the diameters of target lesions; SD, stable disease defined by neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; PD, progressive disease defined by at least a 20% increase in the sum of the diameters of target lesions or the appearance of one or more new lesions.

Within 6 months after initiating study treatment.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
IDH1/2 Mutational Status
Tidsram: Up to 24 months post treatment

Will compare the difference in the objective response rate among patients with IDH1/2 mutations as compared those without IDH1/2 mutations using Fisher's exact test.

Up to 24 months post treatment
Changes in Expression of Conventional Chondrosarcoma Genes
Tidsram: Baseline up to 24 months post treatment

Data from ribonucleic acid sequencing will be analyzed. Differential expression profiles between baseline and on-treatment samples will be analyzed at the gene level and gene expression changes defined as significant based on absolute log2 fold changes > 2 and adjusted p values < 0.005 for each comparison with consideration of the false discovery rate.

Baseline up to 24 months post treatment
Changes in Global Deoxyribonucleic Acid Methylation
Tidsram: Baseline up to 24 months post treatment

A Wilcoxon signed-rank test with continuity correction will be used to calculate P values for comparing methylation level distribution at the different time points.

Baseline up to 24 months post treatment
Changes in Tumor Microenvironment
Tidsram: Baseline up to 24 months post treatment

For quantitative immune multiplexing, data is derived from inForm software, and changes in defined immune cell subsets and expression between baseline and on-treatment samples will be assessed using paired T-tests.

Baseline up to 24 months post treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Mia Weiss, Yale University Cancer Center LAO

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 september 2020

Primärt slutförande (Faktisk)

22 februari 2024

Avslutad studie (Beräknad)

27 januari 2027

Studieregistreringsdatum

Först inskickad

9 april 2020

Först inskickad som uppfyllde QC-kriterierna

9 april 2020

Första postat (Faktisk)

10 april 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NCI-2020-02187
  • UM1CA186686 (U.S.S. NIH-anslag/kontrakt)
  • 10330 (Annan identifierare: CTEP)
  • NCI-2020-02187 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
  • 10330 (Annan identifierare: Yale University Cancer Center LAO)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera